JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4083 Rocilinostat (ACY-1215)
1 Citation

Target: Histone Deacetylases (HDACs)

Summary: Selective HDAC6 inhibitor

≥21.675 mg/mL
A4084 Vorinostat (SAHA, MK0683)
9 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.41 mg/mL
A4089 Mocetinostat (MGCD0103, MG0103)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor,isotype-selective and potent

insoluble in EtOH; insoluble in H2O; ≥19.8 mg/mL
A4090 JNJ-26481585
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Potent HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL
A4091 PCI-34051
1 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC8 inhibitor,potent and selective

insoluble in H2O; insoluble in EtOH; ≥14.8 mg/mL
A4093 ITF2357 (Givinostat)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

≥23.8 mg/mL
A4071 Fluorouracil (Adrucil)
3 Citation

Target: Thymidylate Synthase

Summary: Antitumor agent;inhibitor of thymidylate synthase

insoluble in EtOH; ≥10.04 mg/mL
A4163 UPF 1069

Target: PARP

Summary: Selective PARP2 inhibitor

insoluble in H2O; ≥12.7 mg/mL
A4164 AZD2461

Target: PARP

Summary: Novel PARP inhibitor

insoluble in H2O; ≥16.35 mg/mL
A4094 MC1568
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Class II HDAC inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥15.7 mg/mL